Inclusion | Exclusion |
---|---|
Adults (aged ≥20 years) | Type 1 diabetes mellitus |
T2DM patients who need to start or who are possibly changing or adding an anti-diabetic agent | History of diabetic ketoacidosis, diabetic coma, or hypoglycemic attack ≤6 months prior to informed consent |
CHF (NYHA functional classification I to III) | Severe renal dysfunction (eGFRÂ <45Â ml/min/1.73Â m2) or patients receiving dialysis |
Without change in NYHA functional classification or drugs for heart failure 4Â weeks prior to eligibility | Severe liver dysfunction (at least threefold higher AST or ALT more than the upper limit of the facilities reference value |
The patient provided written informed consent to participate in the study | CHF (NYHA functional classification IV) |
Patients with pituitary or adrenal dysfunction | |
Patients with malnutrition, starvation, irregular eating pattern, lack of dietary intake, or debilitation | |
Patients with excess alcohol intake | |
Patients in perioperative period around trial screening | |
Patients with severe infection or trauma at trial screening | |
Patients with a gastrointestinal disorder, such as diarrhea or vomiting | |
Patients with low body weight (BMIÂ <18.5Â kg/m2) | |
History of coronary artery disease, coronary vascularization, open-heart surgery, stroke, or transient ischemic attack ≤3 months prior to eligibility | |
Patients with a malignancy | |
History of hypersensitivity to ingredients of SGLT2 inhibitors or sulfonylureas | |
Pregnant or suspected pregnancy in females | |
Lactating female | |
Considered inappropriate for the study by investigators due to other reasons |